PET/CT for the staging and follow-up of patients with malignancies.
about
Advance of molecular imaging technology and targeted imaging agent in imaging and therapyApplication of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinomaIs there a role for PET-CT and SPECT-CT in pediatric oncology?Imaging and 'omic' methods for the molecular diagnosis of cancer.Respiratory-gated PET/CT versus delayed images for the quantitative evaluation of lower pulmonary and hepatic lesions.18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and bApplications of molecular MRI and optical imaging in cancer.FDG-PET staging and importance of lymph node SUV in head and neck cancer.Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat modelReal-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation.FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series.Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinomaMultimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.Pulmonary Nodule Detection in Patients with a Primary Malignancy Using Hybrid PET/MRI: Is There Value in Adding Contrast-Enhanced MR Imaging?The future of hybrid imaging-part 2: PET/CT.Image fusion and navigation platforms for percutaneous image-guided interventions.A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary sitePotential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagusQuantitative multimodality imaging in cancer research and therapyMultimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.Desmoplastic fibroma of the scapula with fluorodeoxyglucose uptake on positron emission tomography: a case report and literature review.Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies.Nuclear imaging of autoimmunity: focus on IBD and RA.Convergence technology in cancer medicine.MR evaluation of response to targeted treatment in cancer cells.Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis.[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients: present and future applications.PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy.Edge Artifacts in Point Spread Function-based PET Reconstruction in Relation to Object Size and Reconstruction Parameters.Utility of respiratory-gated small-animal PET/CT in the chronologic evaluation of an orthotopic lung cancer transplantation mouse model.18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation.The edge artifact in the point-spread function-based PET reconstruction at different sphere-to-background ratios of radioactivity.Comparison of PET/CT with conventional imaging modalities (USG, CECT) in evaluation of N0 neck in head and neck squamous cell carcinoma.Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptideIs (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?
P2860
Q26851887-8CD9B509-AEB3-42CE-AE21-73A44BB747E9Q27026961-7F6D351B-6176-4407-A123-5A6EE984C125Q30586066-69F06723-FA88-4A1D-A1B2-34582A8A160EQ33577268-008A3377-BDC1-435D-8D0F-5CFE48BAE3CBQ33706999-DA8E93D4-8352-4FA2-BC51-66B2B8E54A1AQ33823389-9969EC99-C217-44D0-8D11-61D1BE19052CQ33986159-A15C79BD-4CED-4511-AC9D-98D1F6EB2FDCQ34043837-575ED9FD-AFB1-4576-B6D7-A1C1C5370CBAQ34066524-2F0A2338-43AD-4B45-8062-ACA9EF7C9C55Q34075225-2102253E-9C17-4156-A3CF-8B037981220AQ34591066-32DFD82C-7615-43B5-9EBB-6A670ACF1E47Q35167410-6C8A59C1-6DEF-4DB1-B6C3-4557E8930D48Q35318476-0BA4AD15-F72B-4F5D-A859-979C51CE0669Q35402047-710B7DDA-0CEC-439B-91B0-B8E594AD85C1Q35637118-4F3F61DD-980C-46CF-BC3F-F0603111A19BQ35660961-BD0A977D-BE47-43ED-8B95-8F35BC9E9D5FQ35786046-AAF2B660-86BB-4EB2-B2D5-D0484ED3A2F3Q35908774-3DD2F271-907C-4DB1-ADC1-8668E43E983FQ36251449-2B96F0E7-A936-4BE3-BC59-E5F12231784BQ36623646-B3DA740E-63AA-4D88-A8AB-87E2E864515EQ37007810-34FB77EE-CA12-4363-8C41-2A828DE63F6EQ37134628-2050579B-62A7-4ED7-9F52-6448D786B8EEQ37228911-AE10C9CC-213F-48FA-AF0C-4BF0C54E86C6Q37314320-EEA5C245-2803-41C0-8CCB-F04B7CF00AFFQ37730107-4BDD4DCB-6388-4413-8E85-6535A1106BF7Q37850452-91039FD7-CE15-4D1D-9C89-AC4D7848D28AQ37851076-6704199F-8DAC-4FA5-95E3-5DAE9450D81EQ37942070-5E5275E3-04D6-4885-B893-7F80B8084338Q37987555-115A3403-E5F1-4A15-A0C0-84B6CFF3ED8DQ38004182-48D721E5-B9E8-4D5A-9C81-0D216D2CA234Q38018970-FA461B7E-FB08-4B6C-B22D-930A8A8256B0Q38393463-51404A22-79AB-4040-85E2-8127BFDF1CA7Q38550755-2EEA9FD1-34F1-43CA-8F5F-6BF56752F5E1Q38703416-7DDABF1A-C665-456E-800A-8B73A1865C36Q38881186-680A66D7-BC25-4F0B-AB2E-41526AB7B459Q40067112-4155C5A6-6BE3-4E97-9BB1-B8C79241F96EQ40359533-A7CCC84A-2BE5-4866-9DBE-31DF67603A7FQ42020288-FCB16302-7222-4F45-8528-DD8BA11D74F4Q42850578-08FD25CD-CC7F-4B8A-8185-E59A4E960B7CQ45058450-361F422C-CC93-4979-A7EE-A8993E0425BD
P2860
PET/CT for the staging and follow-up of patients with malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PET/CT for the staging and follow-up of patients with malignancies.
@en
PET/CT for the staging and follow-up of patients with malignancies.
@nl
type
label
PET/CT for the staging and follow-up of patients with malignancies.
@en
PET/CT for the staging and follow-up of patients with malignancies.
@nl
prefLabel
PET/CT for the staging and follow-up of patients with malignancies.
@en
PET/CT for the staging and follow-up of patients with malignancies.
@nl
P2093
P1476
PET/CT for the staging and follow-up of patients with malignancies.
@en
P2093
P304
P356
10.1016/J.EJRAD.2009.03.051
P577
2009-04-29T00:00:00Z